AXGN · available-data snapshot
Axogen, Inc. (AXGN): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for Axogen, Inc. (AXGN); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for AXGN?
We do not publish a fair value for Axogen, Inc.. What we can say from its filings and market data is below.
What is AXGN's TickerWorth Score?
Priced richly vs peers — the business scores well
Compared with Healthcare companies in US
Its strongest point: strong balance sheet. Its weakest: trades above our estimate of what it's worth.
- Value · 30 of 100
Cheaper than 30% of Healthcare companies in US
- Price vs worth · 6 of 100
- Quality · 37 of 100
More profitable than 37% of Healthcare companies in US
- Financial health · 83 of 100
Financially stronger than 83% of Healthcare companies in US
- Growth · 78 of 100
Growing faster than 78% of Healthcare companies in US
- Momentum · 59 of 100
Outperformed 59% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $34.58
- Market cap
- $2,
028, 861, 056 - 52-week high
- $52.91
- 52-week low
- $16.65
- Currency
- USD
- Exchange
- NasdaqCM
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for Axogen, Inc. (AXGN) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, AXGN trades at a recent price of $34.58, a market capitalisation of about $2,028,861,056, sitting 49% of the way up its 52-week range ($16.65–$52.91), on the NasdaqCM.
The standard alternative to a DCF is relative valuation — comparing AXGN's trading multiples against a sector benchmark. Here that gives Fwd P/E of 48.0× (richer than the peer median of 17.5×); P/B of 7.2× (in line with the peer median of 7.8×); P/S of 8.1× (richer than the peer median of 6.2×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. AXGN shows a price-to-book (P/B) of 7.24 and book value of $4.78 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. AXGN is in a mixed trend, trading -34.6% from its 52-week high. Over the past year the stock is +104.0%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
AXGN vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | AXGN | Peer median | Read |
|---|---|---|---|
| Fwd P/E | 48.0× | 17.5× | richer than |
| P/B | 7.2× | 7.8× | in line with |
| P/S | 8.1× | 6.2× | richer than |
What does Axogen, Inc. do?
What does it do?
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It operates in the Medical Devices industry (Healthcare sector), headquartered in United States. The company employs roughly 622 people.
How does it make money?
The business turns $225M in annual revenue into profit. Out of every $100 of sales, about $0 is left as operating profit (operating margin of -3.1%), after a 75% gross margin on the products/services it sells. After all costs, taxes and interest, -13.4% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks solid: carries modest debt (0.1× equity), comfortably covers its short-term bills (6.6× current ratio), and is currently lossmaking.
Who at AXGN filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| TYNDALL JOSEPH A. | Director | Open-market sale | $173,939.50 | Form 4 for TYNDALL JOSEPH A. (opens sec.gov in a new tab) | |
| Wendell Amy McBride | Director | Option exercise | $198,292.05 | Form 4 for Wendell Amy McBride (opens sec.gov in a new tab) | |
| Wendell Amy McBride | Director | Open-market sale | $646,592.32 | Form 4 for Wendell Amy McBride (opens sec.gov in a new tab) | |
| Began Marc A | EVP & General Counsel | Option exercise | $550,800.00 | Form 4 for Began Marc A (opens sec.gov in a new tab) | |
| Began Marc A | EVP & General Counsel | Open-market sale | $3,195,787.50 | Form 4 for Began Marc A (opens sec.gov in a new tab) | |
| Weiler Kathy Johnson | Director | Open-market sale | $640,966.70 | Form 4 for Weiler Kathy Johnson (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.